We are live on ! Find out more
AZN icon

AstraZeneca

403 hedge funds and large institutions have $7.09B invested in AstraZeneca in 2014 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 123 increasing their positions, 136 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more call options, than puts

Call options by funds: $958M | Put options by funds: $511M

25% more funds holding in top 10

Funds holding in top 10: 810 (+2)

23% more capital invested

Capital invested by funds: $5.76B → $7.09B (+$1.34B)

14% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 49

1% more ownership

Funds ownership: 6.39%7.39% (+1%)

0% more funds holding

Funds holding: 401403 (+2)

10% less repeat investments, than reductions

Existing positions increased: 123 | Existing positions reduced: 136

Holders
403
Holders Change
+2
Holders Change %
+0.5%
% of All Funds
10.75%
Holding in Top 10
10
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+25%
% of All Funds
0.27%
New
56
Increased
123
Reduced
136
Closed
49
Calls
$958M
Puts
$511M
Net Calls
+$447M
Net Calls Change
+$28.2M
Name Holding Trade Value Shares
Change
Change in
Stake
FPFS
401
First Personal Financial Services
North Carolina
$1K +$1.22K +17 New
BRWA
402
B. Riley Wealth Advisors
Florida
$439 -$118K -1,654 -21%
Manulife (Manufacturers Life Insurance)
403
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$317 +$322K +4,497 New
YCMGA
404
York Capital Management Global Advisors
New York
-$37.8M -528,688 Closed
LBA
405
Letko, Brosseau & Associates
Quebec, Canada
-$37M -518,105 Closed
JCI
406
Jet Capital Investors
New York
-$14.3M -200,000 Closed
Franklin Resources
407
Franklin Resources
California
-$13.7M -192,210 Closed
SFM
408
Soros Fund Management
New York
-$10.7M -150,000 Closed
Jane Street
409
Jane Street
New York
-$10.6M -147,678 Closed
D.E. Shaw & Co
410
D.E. Shaw & Co
New York
-$7.94M -110,929 Closed
Allianz Asset Management
411
Allianz Asset Management
Germany
-$7.5M -105,014 Closed
AIM
412
Allen Investment Management
New York
-$7.5M -105,000 Closed
LOM
413
Loeb Offshore Management
New York
-$6.43M -90,064 Closed
WC
414
Wexford Capital
Florida
-$5.77M -80,739 Closed
Two Sigma Investments
415
Two Sigma Investments
New York
-$4.16M -58,244 Closed
ACPU
416
Arrowgrass Capital Partners (US)
Delaware
-$3.98M -55,727 Closed
LM
417
Lincluden Management
Ontario, Canada
-$3.43M -52,800 Closed
TAL
418
TIG Advisors LLC
New York
-$3.32M -46,526 Closed
MCA
419
Metropolitan Capital Advisors
New York
-$2.64M -36,870 Closed
MCM
420
Moore Capital Management
New York
-$2.14M -30,000 Closed
NCCM
421
Nine Chapters Capital Management
New Jersey
-$1.54M -21,500 Closed
WAS
422
Winch Advisory Services
Wisconsin
-$1.07M -15,004 Closed
WA
423
WESPAC Advisors
California
-$885K -12,395 Closed
OAM
424
Oxford Asset Management
United Kingdom
-$710K -9,920 Closed
CP
425
Camelot Portfolios
Ohio
-$652K -9,123 Closed

AZN Hedge Fund Activity: Q4 2014 in Review

403 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q4 2014, worth a combined $7.09B — up 23% from $5.76B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new AZN positions and 49 closed out — a net gain of 7 holders — while 123 added to existing stakes and 136 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $457M. The largest seller was Susquehanna International Group, cutting an estimated $83.6M.

  • 403 institutional investors held AstraZeneca (AZN) as of Q4 2014, up from 401 in Q3 2014.
  • Funds reported $7.09B of AstraZeneca stock for Q4 2014, up 23% quarter-over-quarter.
  • 56 funds opened new AstraZeneca positions in Q4 2014 and 49 closed out, a net change of +7 holders.
  • The largest AstraZeneca buyer in Q4 2014 was Wellington Management Group, an estimated $457M added.
  • The largest AstraZeneca seller in Q4 2014 was Susquehanna International Group, an estimated $83.6M sold.

Based on aggregated 13F filings for Q4 2014.